Denali Therapeutics Inc.
DNLI
$20.59
-$0.11-0.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 97.91M | 101.95M | 102.70M | 116.23M | 99.79M |
| Gross Profit | -97.91M | -101.95M | -102.70M | -116.23M | -99.79M |
| SG&A Expenses | 39.46M | 35.48M | 32.27M | 29.35M | 30.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.37M | 137.43M | 134.96M | 145.58M | 129.85M |
| Operating Income | -137.37M | -137.43M | -134.96M | -145.58M | -129.85M |
| Income Before Tax | -128.45M | -126.90M | -124.12M | -132.97M | -114.69M |
| Income Tax Expenses | 102.00K | -- | -- | -- | 68.00K |
| Earnings from Continuing Operations | -128.55M | -126.90M | -124.12M | -132.97M | -114.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.55M | -126.90M | -124.12M | -132.97M | -114.75M |
| EBIT | -137.37M | -137.43M | -134.96M | -145.58M | -129.85M |
| EBITDA | -133.58M | -133.57M | -131.01M | -142.37M | -127.23M |
| EPS Basic | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
| Normalized Basic EPS | -0.46 | -0.46 | -0.45 | -0.50 | -0.44 |
| EPS Diluted | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
| Normalized Diluted EPS | -0.46 | -0.46 | -0.45 | -0.50 | -0.44 |
| Average Basic Shares Outstanding | 175.46M | 172.42M | 171.45M | 171.22M | 170.09M |
| Average Diluted Shares Outstanding | 175.46M | 172.42M | 171.45M | 171.22M | 170.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |